Moscow City Hospital #11

Moscow

0 studies enrolling now · 2 studies all time

What they study most

Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed